Navigation Links
Warner Chilcott Announces FDA Approval of New Oral Contraceptive
Date:10/22/2010

licies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded pharmaceuticals business from The Procter and Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009, and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive.  In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur.  We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
2. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
3. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
4. Warner Chilcott Announces FDA Approval of Next Generation Actonel
5. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
6. Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex®
7. Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
8. Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex®
9. Warner Chilcott to Present at UBS Global Life Sciences Conference
10. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
11. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... PAUL, Minn. , July 29, 2014  EnteroMedics ... medical devices using neuroblocking technology to treat obesity, metabolic ... will host a conference call on Thursday, August 7, ... results for the second quarter ended June 30, 2014 ... Call Details The second quarter conference call ...
(Date:7/29/2014)... New high priced hepatitis C drugs will increase federal ... to $5.8 billion next year, according to a new ... the Pharmaceutical Care Management Association (PCMA). Milliman projects that ... as 8.6 percent in 2015 as a result of ... The study finds that the majority of new ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Drew Crawford Announces Launch of PBM365 Media 2
... PALM BEACH, Fla., Dec. 15, 2011  China Nuvo Solar ... has recently conducted its first mobile product fair demonstration ... products.  The product fair was recently held and the ... and the Third-Party Consulting Company that has been contracted ...
... 2011  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.  Isis ... 12:00 p.m. Eastern Time to provide more detail on ... been an extremely successful year for Isis and positions ...
Cached Medicine Technology:China Nuvo Solar Energy, Inc./SurgLine Announces New Mobile Marketing Campaign 2Isis Adds Three New Drugs to Its Development Pipeline 2Isis Adds Three New Drugs to Its Development Pipeline 3Isis Adds Three New Drugs to Its Development Pipeline 4Isis Adds Three New Drugs to Its Development Pipeline 5
(Date:7/29/2014)... 29, 2014 As the Ebola outbreak in ... partners to both purchase critical emergency supplies locally, as well ... Liberia. These supplies will contain materials used to control the ... populated areas of the country. , With a large ... response to the Ebola outbreak in the region. The current ...
(Date:7/29/2014)... July 29, 2014 The Board of Governors ... & Hart LLP ’s Connie Akridge to serve ... serves as President of the Foundation. Akridge served as President ... is a partner at Holland & Hart in Las Vegas, ... regulatory/administrative matters to insurance and healthcare clients for more than ...
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... leading pediatricians have joined our network, CarePoint Health ... and Dr. Sushma Kaki. Hundreds of highly skilled ... a comprehensive network of top doctors and practices ... specialties. This latest acquisition represents CarePoint Health’s commitment ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tylenol ... individuals who allegedly suffered serious liver injuries due ... move forward in a multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated ... deadlines pertaining to bellwether case and discovery issues. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Historically, Memorial ... the United States usually celebrated throughout that time by ... those summer days now mark the start of a ... involving teen drivers. In 2012 nearly 1.000 people ... period from Memorial Day to Labor Day. , The ...
Breaking Medicine News(10 mins):Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2
... 8, 2011) -- Today at the Neglected Tropical Diseases ... in Boston, the Drugs for Neglected Diseases initiative (DNDi) ... new helminth infection drug portfolio to address unmet needs ... project will assess the potential of the drug flubendazole ...
... from a new study revealed that men who smoke had ... who never smoked. Researchers also reported that men who were ... likely to need arthroplasty. Details of this study are now ... Wiley-Blackwell on behalf of the American College of Rheumatology (ACR). ...
... Contrary to popular belief, so-called hypoallergenic dogs do not have ... conclusion of a study by Henry Ford Hospital researchers who ... allergen in the home than other dogs. Hypoallergenic dogs are ... fur. The findings are to be published online this ...
... "A debt ceiling agreement must be reached in time to ... patients who rely on Medicare, Medicaid and other federal health ... American College of Physicians (ACP) told the president, vice president ... our views on enactment of legislation to increase the debt ...
... that could stop the growth of glioblastoma, a deadly form ... journal Cell , a Cell Press publication, a new ... allows them to grow and seed tumors. Importantly, normal stem ... that same dependency. "When thinking about therapeutics [targeting cancer ...
... 2011Companies that try to increase sales of their products ... imply that they support breast cancer researcha practice called ... chemicals shown to cause cancer are committing a form ... article in Environmental Justice, a peer-reviewed journal ...
Cached Medicine News:Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 2Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 3Health News:Male smokers less likely to need joint replacement surgery of hip or knee 2Health News:Study: Hypoallergenic dogs not less allergic than other dogs 2Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 2Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 3Health News:To combat deadly brain cancer, target the stem cells 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: